Interim report on the A/H1N1 influenza virus pandemic in Marseille, France, April-November 2009  by Nougairede, A. et al.
Interim report on the A/H1N1 influenza virus pandemic in Marseille,
France, April-November 2009
A. Nougairede1,2, L. Ninove1,2, C. Zandotti2, S.-D. Thiberville1,3, C. Gazin2, B. La Scola2, R. N. Charrel1,2 and
X. de Lamballerie1,2,4
1) Unite´ des Virus Emergents, UMR190, Universite´ de la Me´diterrane´e et Institut de Recherche pour le De´veloppement, Marseille, 2) Laboratoire de Virolo-
gie, Poˆle hospitalier de Microbiologie et Maladies Infectieuses, Assistance Publique, Hoˆpitaux de Marseille, 3) Service des Maladies Infectieuses et Tropicales,
CHU Nord, Poˆle hospitalier de Microbiologie et Maladies Infectieuses, Assistance Publique, Hoˆpitaux de Marseille and 4) Ecole des Hautes Etudes en Sante´
Publique, Rennes, France
Abstract
We report here the results of a 7-month survey of the influenza A/H1N1 pandemic in the Virology laboratory of the public hospitals of
Marseille (April–November 2009). In total, 8 587 samples were analysed during this period, of which 1 974 (23%) were positive for the
novel influenza variant. The analysis of results obtained using rapid influenza diagnostic tests (RIDTs) revealed a global sensitivity of
49.4% (vs. molecular qRT-PCR detection), strongly correlated with age groups (varying from 30% to 58% for patients >40 age and <10,
respectively), indicating that RIDTs can be helpful in accelerating the management of suspected cases. Epidemiological analysis showed
that the winter influenza wave began in October in Marseille (i.e. 2 to 3 months earlier than usual seasonal influenza outbreaks) and
that the majority of autochthonous cases were observed in patients younger than 20 years old, with a low number of cases in patients
over 60 years old. In November 2009, 22.2% (167/754) of patients with a laboratory diagnosis of influenza A/H1N1 infection were hos-
pitalized, of which 9% (15/167) were admitted to an intensive care unit (ICU). Patients in the extreme age groups (>40 years old and
<1) were significantly more often hospitalized than others, and 2.4% of hospitalized patients died. During the last 3 weeks of the period,
the average number of bed-days attributable to H1N1sw-positive patients was 31.4, of which 5.9 were in ICUs.
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Introduction
In late April 2009, a novel A/H1N1 influenza virus (H1N1sw)
was isolated in North America [1]. Rapidly, the World Health
Organization increased the alert level from phase 5 to phase
6, defining the first influenza pandemic of the 21st century
[2]. The first wave affected Mexico, the USA and Canada with
severe cases and deaths [3–5]. The following wave affected
the southern hemisphere during the southern winter season
[6,7], and once again severe cases were observed; over
3 months, 722 patients were admitted to an Intensive Care
Unit (ICU) in Australia or New Zealand, representing 28.7
cases per million inhabitants, with a 14.3% mortality [8].
The first cases in metropolitan France were detected in
April 2009 in patients returning from Mexico. Until early July
2009, a systematic surveillance based on laboratory confir-
mation of suspected cases was implemented in the ‘Level A’
laboratories of the seven French Defence Zones [9]. During
the following months, laboratory confirmation was mainly
performed in groups at risk and in hospitalized patients.
We report here data collected by the ‘Level A’ Virology
laboratory of the public hospitals of Marseille (Southern
Defence Zone) from 25 April to 29 November 2009; the
evolution of the outbreak, the distribution among age
groups, the results of rapid influenza diagnostic tests (RIDTs)
and the characteristics of hospitalized patients are described
and discussed.
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All clinical nasal samples were obtained using Virocult swabs
(Virocult MW950; Medical Wire and Equipment Co.). Labo-
ratory investigations for diagnostic purposes and epidemio-
logical assessment, warranted by patients’ signatures at the
hospital entrance office, were performed in accordance with
French national regulations (Huriet-Se´rusclat law, #881138)
and did not require ethical committee approval.
Rapid influenza diagnostic testing (RIDT)
RIDT was performed using the Directigen EZ influenza A+B
test (BD EZ Flu A+B, Becton, Dickinson and Company)
according to the manufacturer’s instructions.
RNA extraction
Samples were spiked with in-house MS2 phage internal con-
trol [10] and RNA was extracted using the EZ1 Virus Mini
Kit v2 on the EZ1 Biorobot (both from Qiagen).
Quantitative real time PCR assays
Samples were analysed by two qRT-PCR assays: (i) a qRT-
PCR assay using SYBR Green technology detecting all influ-
enza A viruses [10], and (ii) a qRT-PCR assay specific for
H1N1sw, recommended by the French Influenza Reference
National Centre [9] as previously described.
Database of patients infected by H1N1sw
During the last 4 weeks of the study (November 2009) data
regarding in-patients and patients presenting at the hospital
emergency department with a subsequent laboratory confir-
mation of H1N1sw infection were collected from the data-
base of the public hospitals of Marseille. The age, sex, arrival
and discharge from hospital dates, category of hospitalization
unit (paediatric medical unit, adult medical unit, paediatric
ICU and adult ICU) and number of deaths were analysed
using an anonymized database.
Results
From 25 April to 29 November 2009, we analysed 8 587
specimens for detection of the novel A/H1N1 virus. A total
of 5 848 (68.1%) originated from public hospitals in Marseille,
the remaining samples being sent by other hospitals from the
French South Defence Zone. Until late June the numbers of
samples tested remained low but they increased progres-
sively until early September (Fig. 1). During this period, the
percentage of H1N1sw-positive samples remained stable at
c. 10%. In September, the number of samples increased sud-
denly but the percentage of H1N1sw-positive samples
decreased (Fig. 1). This episode was associated with the cir-
culation of other respiratory viruses such as rhinoviruses and
coronaviruses. The influenza winter wave began effectively in
October (weeks 41–42) with a marked increase of both tested
and positive samples. From late October, the percentage of
H1N1sw-positive samples remained stable (30–40%) but the
number of positive samples continued to increase (Fig. 1).
We analysed the distribution among age groups of tested
samples (N) and H1N1sw-positive samples (N¢) during the
study period. Until late August, patients over 20 years old
represented 60% of all tested patients and more than 50% of
H1N1sw-positive patients. During this period, patients in
the 10–19 years age group represented 30% of H1N1sw-
positive patients (Fig. 2a,b) but this proportion increased in
September (weeks 36–38), to reach more than 40% of
infected patients. From mid-September, the proportion of
patients younger than 10 years who were tested or infected
by H1N1sw increased, representing approximately 40% of
both groups and the distribution among age groups remained
globally stable afterwards (Fig. 2a,b). The N¢/N ratio (allow-
ing standardization of the number of samples in the age
groups) showed that the highest proportion of positive
patients was observed in the 10–19 years age group (30–
60%) and that this proportion fluctuated c. 20% for patients
over 40 years old (Fig. 2c). During the complete study
period the majority of patients infected by H1N1sw were
younger than 20 years old.
Among the 8 587 samples tested for influenza virus using
qRT-PCR, a total of 7 459 (including 1615 qRT-PCR positive
with both systems) were also tested using RIDT. Of the
7 459 samples, 798 (10.7%) gave positive results in the RIDT,
all of these being positive for molecular detection of the
FIG. 1. Time distribution of samples tested and samples positive for
H1N1sw during 7 months in the Virology laboratory of the public
hospitals of Marseille.
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H1N1sw influenza virus (specificity of RIDT = 100%, sensitiv-
ity = 49.4%). There was a strong correlation between RIDT
sensitivity and age (Fig. 3): the sensitivity varied between
30% and 58% for patients in the ‡40 and <10 years age
groups, respectively. Furthermore, from mid-October, the
performance of RIDT detection was correlated with the pro-
portion of patients infected who were younger than 20 years
(Fig. 2b).
Among the 754 H1N1sw-positive patients admitted to the
public hospitals of Marseille during the last 4 weeks of this
study (weeks 45–48), 167 (22.2%) were hospitalized and four
died (2.4% of hospitalized patients). Comparison of hospital-
ized and non-hospitalized patients showed comparable sex
ratios (M/F, 0.99 and 0.92, respectively) and median ages (14.5,
range: 0–98 years, and 11.3, range: 0–99 years, respectively).
The age distribution was similar in hospitalized and non-
hospitalized patients except for patients younger than 1 year
and over 40 years. Overall, 24.0% of in-patients and 10.1% of
non-hospitalized patients were over 40 years (v2 test:
p <0.0001) and 15.6% of in-patients and 5.7% of non-hospital-
ized patients were under 1 year (v2 test: p <0.0001). Among
167 hospitalized patients, 15 (9.0%, and 2.0% of all 754
infected patients) were admitted to an ICU because of severe
clinical conditions. The median age of patients hospitalized in
an ICU was 23.7 years (range: 1 month–61 years). Of patients
hospitalized in ICUs 40% were over 40 years and 13.3% were
under 6 months. From 9 November to 29 November, the
average number of bed-days due to H1N1sw-positive patients
in the public hospitals of Marseille was 31.4 (95% CI, 29.5 to
33.4 days) of which 5.9 (95% CI, 5.4 to 6.4) were in ICUs. Half
and 32.5% of bed-days were attributable to children (under
18 years) in medical units and ICUs, respectively (Fig. 4).
Among patients hospitalized in medical units, 21.1% and 61.3%
stayed in hospital for 2 days or less and for 4 days or less,
respectively (range: 1–23 days), while 12.5% of patients hospi-
talized in ICUs stayed in hospital 4 days or less and 50% stayed
in hospital 13 days or more (range: 4–29 days).
Discussion
The retrospective analysis of the first 7 months (from late
April to late November; weeks 17–48) of the wave of
FIG. 2. Distribution among age groups of samples tested (N) (a), sam-
ples positive for H1N1sw (N¢) (b) and for the N¢/N ratio (correspond-
ing to the standardization of number of samples in age groups) (c).
The evolution of RIDT sensitivity is indicated for weeks 41–48 (b).
FIG. 3. Sensitivity of RIDT according to age groups amongst 1 615
samples positive for H1N1sw.
FIG. 4. Daily occupancy of the paediatric and adult medical unit and
of the paediatric and adult ICU during 4 weeks in public hospitals of
Marseille.
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H1N1sw pandemic infections in the region of Marseille
(south-eastern France) indicates that three periods with dis-
tinct epidemiological characteristics can be distinguished. The
very first imported cases were observed from April to
August in travellers returning from abroad (mainly Mexico
and the USA), and thus with a majority of adults [9]. In the
second phase, with indigenous cases, which became predomi-
nant during the summer, the number of paediatric cases
(<10 years old) increased progressively to reach a stable
proportion of approximately 40% of all cases. Consequently,
the global distribution among age groups became comparable
to that previously observed for seasonal H1N1 outbreaks
[11], with a majority of cases in patients younger than
20 years, confirming data from other countries [7,12]) and a
low number of patients over 60 years old. The final phase, a
‘winter’ wave, began in Marseille during October (as was also
observed in other regions of metropolitan France [13])
2–3 months before the classic winter wave of seasonal
influenza.
The use of a RIDT is common for the diagnosis of sea-
sonal influenza. Whether ‘classical’ tests (designed for detec-
tion of seasonal A/H3N2, A/H1N1 and B viruses) could be
used for the detection of the new A/H1N1sw variant was
uncertain and contrasting results had been obtained using
various available commercial kits [13–16]. Our results sug-
gest that RIDTs could make a significant contribution to the
management of suspected cases. They allowed more rapid
delivery of positive diagnosis (<2 h) for 49.4% of the
H1N1sw-positive samples, the highest sensitivity (close to
60%) being obtained in children younger than 10 years.
Other studies showed a similar sensitivity for the detection
of this new variant [13] and an equal analytical sensitivity
between seasonal influenza and this new variant [14] using
the BD EZ Flu A+B test.
Finally, the follow up organized during November indi-
cated that 22.2% of patients with a documented H1N1sw
infection were hospitalized and that 2.4% of hospitalized
patients died. Approximately 30 bed-days were attributable
to H1N1sw in the public hospitals of Marseille, of which six
were in ICUs. Since the public hospitals of Marseille serve a
population of approximately one million inhabitants, these
numbers are similar to those encountered in surveys previ-
ously performed in Australia and New Zealand [8]. Impor-
tantly, our results indicate that the duration of
hospitalization was short for patients admitted to medical
units, but also that the pattern of hospitalization observed
(children younger than 1 year and patients over 40 years
being significantly more frequently hospitalized than others)
was reminiscent of the U-shaped age-distribution curve
previously reported for seasonal influenza.
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